Christine Martinez‐Vinson

Hôpital Robert-Debré

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Jean‐Pierre Hugot

Hôpital Robert-Debré

Jérôme Viala

Hôpital Robert-Debré

M. Bellaïche

Hôpital Robert-Debré

Catherine Badens

Génétique Médicale & Génomique Fonctionelle

Dominique Berrebi

Université Paris Cité

Alexandre Fabre

Aix-Marseille Université

Frank M. Ruemmele

Hôpital Necker-Enfants Malades

Jiří Bronský

University Hospital in Motol

Claire Dupont

Université de Caen Normandie

D. Berrebi

Hôpital Necker-Enfants Malades

Cooperative Institutions

Inserm

161

Assistance Publique – Hôpitaux de Paris

131

Université Paris Cité

122

Hôpital Robert-Debré

Sorbonne Paris Cité

Sorbonne Université

Centre National de la Recherche Scientifique

Délégation Paris 7

Hôpital Necker-Enfants Malades

Délégation Paris 5

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Bone Health in Pediatric Patients With Crohn Disease

Journal of Pediatric Gastroenterology and Nutrition (2021)

Sylvana Rozes Sophie Guilmin‐Crépon Marianne Alison Thomas Édouard Jean‐Pierre Hugot

The aim of our study was to examine longitudinal changes in bone mineral density (BMD) of children and adolescents with Crohn disease (CD), and risk factors related to low BMD.All patients ages from 2 to 18 years with CD who underwent dual-energy X-ray absorptiometry (DXA) at diagnosis and at the end of follow-up between 1999 and 2018 were considered for inclusion in this retrospective study. Factors related to changes in BMD at diagnosis and during follow-up were investigated.One hundred and ninety-three patients had the two DXA required. At diagnosis, 36 patients (18.7%) had a low BMD.At the end of follow-up, 31 patients (16%). One hundred and sixty-four patients did not have the two DXA required.In included CD, BMD values were lower in the lumbar spine (LS) than in total body less head (TBLH), as well at diagnosis (P < 0.0001) or at the end of follow-up (P = 0.001).At diagnosis, only growth impairment or low BMI was associated with low BMD (P < 0.0001), only cumulative dose of corticosteroid at the end of follow-up (P = 0.01).The high prevalence of low BMD in children and adolescents with IBD highlights the importance of evaluating BMD in these patients at the time of diagnosis and throughout the course of their treatment. Special attention must be given to patients with height delay or low BMI at diagnosis. Long-term glucocorticoid therapy is the main clinical risk factor associated with low BMD at the end of follow-up.

Dual-Energy X-ray Absorptiometry

10.1097/mpg.0000000000003132

Cite

Citations (7)

Nod2 protects remote small intestinal sites in case of colonic inflammation

bioRxiv (Cold Spring Harbor Laboratory) (2019)

Ziad Al Nabhani Dominique Berrebi Christine Martinez‐Vinson Nicolas Montcuquet Gilles Dietrich

ABSTRACT NOD2 mutations are key risk factors for Crohn’s disease (CD). NOD2 contributes to intestinal homeostasis by regulating innate and adaptive immunity together with intestinal epithelial function. However, the roles of NOD2 during gut inflammation is not known. We initially observed that NOD2 expression was increased in epithelial cells remote from inflamed areas in CD patients. To explore this finding, Nod2 mRNA expression, inflammation and gut permeability were examined in the small bowel of wild-type (WT), Nod2 knockout and Nod2 mutant mice after rectal instillation of 2,4,6-trinitrobenzene sulfonic acid (TNBS). In WT mice, Nod2 upregulation remote to rectal injury was associated with pro-inflammatory cytokine expression, recirculating CD4 + T-cells, increased paracellular permeability and myosin like chain kinase activity. Nod2 knockout or mutation led to duodenitis and ileitis demonstrating the remote protective role of Nod2. Bone morrow stem cell (BMSC) transplantations indicated that the small intestinal inflammation was due to NOD2 loss in both hematopoietic and non-hematopoietic compartments. As a whole, WT but not mutant NOD2 prevents disease extension at sites remote from the initial intestinal injury.

10.1101/510933

Cite

Citations (0)

Robotic-assisted colectomy in children: a comparative study with laparoscopic surgery

Journal of Robotic Surgery (2023)

Garance Martin Louise Montalva Stéphane Paré Liza Ali Christine Martinez‐Vinson

Colorectal Surgery

10.1007/s11701-023-01647-2

Cite

Citations (8)

Functional abdominal pain disorders and patient- and parent-reported outcomes in children with inflammatory bowel disease in remission

Digestive and Liver Disease (2021)

Léa Chantal Tran L. Bridoux‐Henno Swellen Gastineau A. Dabadie Emilie Carré

Chronic abdominal pain occurs frequently in pediatric patients with inflammatory bowel disease (IBD) in remission. To assess the prevalence and factors associated with Functional Abdominal Pain Disorders among IBD children in remission (IBD-FAPD). Patients with IBD for > 1 year, in clinical remission for ≥ 3 months were recruited from a National IBD network. IBD-FAPDs were assessed using the Rome III questionnaire criteria. Patient- or parent- reported outcomes were assessed. Among 102 included patients, 57 (56%) were boys, mean age (DS) was 15.0 (± 2.0) years and 75 (74%) had Crohn's disease. Twenty-two patients (22%) had at least one Functional Gastrointestinal Disorder among which 17 had at least one IBD-FAPD. Past severity of disease or treatments received and level of remission were not significantly associated with IBD-FAPD. Patients with IBD-FAPD reported more fatigue (peds-FACIT-F: 35.9 ± 9.8 vs. 43.0 ± 6.9, p = 0.01) and a lower HR-QoL (IMPACT III: 76.5 ± 9.6 vs. 81.6 ± 9.2, p = 0.04) than patients without FAPD, and their parents had higher levels of State and Trait anxiety than the other parents. Prevalence of IBD-FAPD was 17%. IBD-FAPD was not associated with past severity of disease, but with fatigue and lower HR-QoL.

10.1016/j.dld.2021.05.034

Cite

Citations (4)

P302 Cytomegalovirus infection in pediatric acute severe ulcerative colitis – a multicenter case-controlled study from the Pediatric IBD Porto group of ESPGHAN

Journal of Crohn s and Colitis (2017)

Shlomi Cohen Christine Martinez‐Vinson Marina Aloi Dan Turner Amit Assa

Background: Data on the clinical course and outcomes of pediatric patients with cytomegalovirus (CMV) infection complicating acute severe ulcerative colitis (ASC) is very limited. The aim of our study was to compare the outcome of CMV-positive and negative pediatric ASC. Methods: This was a multicenter retrospective case-controlled study, from centers in Europe and Israel. We included CMV-positive pediatric patients hospitalized for acute severe colitis and compared their outcomes (rate of colectomy during hospitalization and up to 1 year from the hospitalization) to matched CMV-negative controls Results: A total of 56 children from 10 centers were included. The patient cohort included 23 (41.1%) males/ 33 (58.9%) females, with a median age of 11.5 (interquartile range (IQR) – 7–14) years. Fifty-two (92.9%) of the patients had extensive/pan-colitis colitis and the rest left sided colitis, with severe disease in 52 (92.9%) of the patients and moderate in 4 (7.1%). Fifteen patients were CMV-positive and 41 – CMV-negative. Significantly higher proportion of CMV positive patients were resistant to intravenous corticosteroids (p=0.009). After diagnosis of CMV infection, 14/15 patients were started on gancyclovir (5 mg/kg – 5/14 (35.7%) and 10 mg/kg – 9/14 (64.3%). During hospitalization, 3 (20%) CMV positive and 3 (7.8%) CMV-negative patients required colectomy (p=0.17). By 12 months of follow-up, 5 (33.3%) and 5 (12.5%) CMV positive and negative patients required colectomy, respectively (p=0.049). Previous anti-TNF exposure and Pediatric Ulcerative Colitis Activity Index score on index date were significantly associated with the risk of colectomy during hospitalization and by 12 months (p=0.037 and p=0.01 for previous anti-TNF exposure and p=0.021 for PUCAI) on univariate analysis, however none of the factors including CMV positivity retained significance on multivariate analysis. Conclusions: A higher prevalence of CMV positivity was found in pediatric UC patients who required colectomy within 12 months of index hospitalisation, however the difference was not statistically significant on multivariate analysis. Further studies are merited to clarify the impact of CMV infection on the outcome of acute severe colitis in pediatric patients

Interquartile range

Cytomegalovirus

10.1093/ecco-jcc/jjx002.427

Cite

Citations (1)

Comportement alimentaire des enfants et adolescents atteints d’une maladie inflammatoire chronique en période de rémission clinique et biologique sous biothérapie

Nutrition Clinique et Métabolisme (2020)

Gérard Michel Christine Martinez‐Vinson Jean‐Pierre Hugot Emmanuelle Ecochard‐Dugelay

10.1016/j.nupar.2020.02.422

Cite

Citations (0)

Management of Paediatric Patients With Medically Refractory Crohn’s Disease Using Ustekinumab: A Multi-Centred Cohort Study

Journal of Crohn s and Colitis (2018)

Mallory Chavannes Christine Martinez‐Vinson Lara Hart Nicole Kaniki Che‐Yung Chao

Ustekinumab [UST] is effective in the treatment of adults with moderate to severe Crohn's disease [CD]. There is a paucity of data on its use in children.To evaluate the response to UST in children with moderate to severe CD.This multicentre retrospective cohort study identified children under 18 years old with CD, who received open-labelled subcutaneous UST. The primary outcome was changes in mean abbreviated Paediatric Crohn's Disease Activity Index [aPCDAI] between baseline and 3 and 12 months, and rate of clinical remission at 3 and 12 months. Secondary outcomes were clinical response at the same time points, changes in C-reactive protein [CRP] and albumin, improvement in growth parameters, and rate of adverse events.A total of 44 patients who failed at least one biological treatment were identified. Linear mixed model [LMM] analysis revealed a statistically significant effect of UST (χ2[1] = 42.7, p = 1.2 × 10-8) which lowered the aPCDAI scores by about 16 ± 2.7 at 3 months, and 19.6 ± 2.9 at 12 months. At 12 months, 38.6% of the patients achieved clinical remission and 47.8% achieved clinical response. There was a significant increase in mean weight z-score of 0.48 [±0.13] [p <0.001] and in mean body mass index [BMI] z score of 0.66 [±0.16] [p <0.001]. The probability of remaining on UST at 12 months was 76.9%. The rate of adverse events was 12.4 per 1000 patient-months.Subcutaneous UST should be considered a viable therapeutic option for paediatric patients who are refractory to other biological agents. Prospective randomised trials are needed.

Ustekinumab

Refractory (planetary science)

10.1093/ecco-jcc/jjy206

Cite

Citations (57)

Microvillous Atrophy

Journal of Pediatric Gastroenterology and Nutrition (2014)

Ariane Perry Hayet Bensallah Christine Martinez‐Vinson Dominique Berrebi Brigitte Arbeille

Microvillous inclusion disease (MVID) is a cause of intractable diarrhea in infancy. In its classic form, the disease is characterized by a severe persistent watery diarrhea starting within the first days of life. Parenteral nutrition and small bowel transplantation are the only known treatments for the affected children. Histologically, periodic acid-Schiff (PAS) staining shows accumulation of periodic acid-Schiff-positive staining material along the apical pole of enterocytes, whereas transmission electron microscopy exhibits microvillus inclusion bodies within the cytoplasm of enterocytes with rarefied and shortened microvilli and secretory granules. The objective of this work was to explore clinical, morphological, and genetic findings in cases of MVID with unusual presentations.Clinical, histological, and genetic findings are reported for 8 cases of MVID with atypical presentation.The diarrhea started after several months in 3 cases. It was usually less abundant and 3 patients were weaned off parenteral nutrition. None required intestinal transplantation. Three patients experienced malformations, dysmorphy, sensory disabilities, and severe mental retardation. One had a hydrocephaly. Three patients had a cholestasis with low γ-glutamyl transferase levels. Light microscopy showed histological abnormalities consistent with MVID in all of the cases, but the lesions were sometimes focal or delayed. Transmission electron microscopy retrieved some criteria of MVID in 4 patients. Finally, 6 patients were homozygotes or compound heterozygotes for MYO5B mutations.This study extends the spectrum of MVID to less severe clinical presentations.

Periodic acid–Schiff stain

Villous atrophy

10.1097/mpg.0000000000000526

Cite

Citations (36)

Infliximab Paradoxical Psoriasis in a Cohort of Children With Inflammatory Bowel Disease

Journal of Pediatric Gastroenterology and Nutrition (2019)

Olivier Courbette Camille Aupiais Jérôme Viala Jean‐Pierre Hugot Baptiste Louveau

In adult inflammatory bowel disease (IBD) treated by anti-TNF antibodies, paradoxical psoriasis has an estimated prevalence of 1.6 to 22%, especially in infliximab (IFX)-treated patients. Little is known in the pediatric IBD (PIBD) populations.All patients ages from 2 to 18 years with Crohn disease (CD) or ulcerative colitis (UC) and treated for the first time by IFX between January 2002 and March 2014, were considered for inclusion in this retrospective study performed in a tertiary PIBD centre. Paradoxical psoriasis events together with clinical and biological data were collected in all patients. Comparisons between psoriasis and control groups were performed using univariate statistical analyses.One hundred and twenty-three CD patients and 24 UC patients were treated with IFX. Twenty patients (13.6%) experienced a paradoxical psoriasis. All of them were affected by CD. Perianal CD was more frequent in the psoriasis group (P = 0.033). Fourteen patients (70%) were in remission when skin lesions occurred. Paradoxical psoriasis was diagnosed 355 days (median, interquartile range [IQR] 239; 532) after the initiation of IFX corresponding to the eighth injection (median, IQR: 6; 15). Psoriasis lesions were controlled by local steroids in all cases and no patients discontinued IFX therapy.13.6% of our IBD patients treated with IFX developed psoriasis during a median follow-up of 23.9 months (IQR: 11.6; 36.5). Crohn disease patients with perianal disease were at a higher risk to develop this common side effect.

Interquartile range

10.1097/mpg.0000000000002349

Cite

Citations (27)

Clinical Features and Natural History of Paediatric Patients with Ulcerative Proctitis: A Multicentre Study from the Paediatric IBD Porto Group of ESPGHAN

Journal of Crohn s and Colitis (2023)

Noa Tal Christos Tzivinikos Marco Gasparetto Daniela Elena Serban Eyal Zifman

Ulcerative proctitis [UP] is an uncommon presentation in paediatric patients with ulcerative colitis. We aimed to characterize the clinical features and natural history of UP in children, and to identify predictors of poor outcomes.

10.1093/ecco-jcc/jjad111

Cite

Citations (4)